A review of glioblastoma immunotherapy

被引:0
作者
Ravi Medikonda
Gavin Dunn
Maryam Rahman
Peter Fecci
Michael Lim
机构
[1] The Johns Hopkins University School of Medicine,Department of Neurosurgery
[2] Washington University School of Medicine in St. Louis,Department of Neurosurgery
[3] University of Florida,Department of Neurosurgery
[4] Duke University Hospital,Department of Neurosurgery
来源
Journal of Neuro-Oncology | 2021年 / 151卷
关键词
Glioblastoma; Immunotherapy; GBM Immunotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:41 / 53
页数:12
相关论文
共 1664 条
[1]  
Burnet M(1957)Cancer: a biological approach: III. Viruses associated with neoplastic conditions: IV. practical applications Br Med J 1 841-847
[2]  
Burnet FM(1970)The concept of immunological surveillance Prog Exp Tumor Res 13 1-27
[3]  
Thomas L(1961)Cellular and humoral aspects of the hypersensitive states Acta Medica Scandinavica 170 128-128
[4]  
Dunn GP(2004)The immunobiology of cancer immunosurveillance and immunoediting Immunity 21 137-148
[5]  
Old LJ(2002)Cancer immunoediting: from immunosurveillance to tumor escape Nat Immunol 3 991-998
[6]  
Schreiber RD(2018)Cancer immunotherapy using checkpoint blockade Science 359 1350-1355
[7]  
Dunn GP(2012)The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 252-264
[8]  
Bruce AT(2015)Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC) J Clin Oncol 33 LBA109-LBA109
[9]  
Ikeda H(2015)Nivolumab versus everolimus in advanced renal-cell carcinoma New Engl J Med 373 1803-1813
[10]  
Old LJ(2017)Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial Lancet Oncol 18 312-322